Gender differences for initiating teriparatide therapy: Baseline Data from the Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study

Osteoporosis International

Volumn 23, Issue 4, 2012, Pages 1445-1452

  Wong, M ^a   Wan, X ^b   Ruff, V ^b   Krohn, K ^b   Taylor, K ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Lilly USA   (United States)

Author keywords

Gender differences; Observational study; Osteoporosis; Teriparatide

Indexed keywords

GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; BONE DENSITY CONSERVATION AGENT;

ADULT; ARTICLE; BODY MASS; BONE FRAGILITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATIENT ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SCREENING; SEX DIFFERENCE; TREATMENT RESPONSE; AGE DISTRIBUTION; AGED; BONE DENSITY; CLINICAL TRIAL; DRUG EFFECT; FEMUR NECK; HIP; LUMBAR VERTEBRA; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT SELECTION; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PROSPECTIVE STUDY; RECURRENT DISEASE; STATISTICS;

AGE DISTRIBUTION; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DRUG PRESCRIPTIONS; FEMALE; FEMUR NECK; GLUCOCORTICOIDS; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATIENT SELECTION; PROSPECTIVE STUDIES; RECURRENCE; SEX FACTORS; TERIPARATIDE;

EID: 84861750196     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1725-8     Document Type: Article

References (29)

1. Teng GG, Curtis JR, Saag KG (2009) Quality health care gaps in osteoporosis: how can patients, providers, and the health system do a better job? Curr Osteoporos Rep 7:27-34
2. US Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General, 2004. http://www.surgeongeneral. gov/library/bonehealth/. Accessed 2 December 2010
3. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726-1733
4. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010. http://www.nof.org/sites/default/files/pdfs/NOF-ClinicianGuide2009-v7.pdf. Accessed 2 December 2010
5. Campion JM, Maricic MJ (2003) Osteoporosis in men. Am Fam Physician 67:1521-1526
6. Sacco SM, Ward WE (2010) Revisiting estrogen: efficacy and safety for postmenopausal bone health. J Osteoporos 2010:708931
7. Geusens P, Dinant G (2007) Integrating a gender dimension into osteoporosis and fracture risk research. Gend Med 4(SUPPL. B): S147-S161
8. Adler R, Curtis J, Weinstein RS, Saag KG (2010) Glucocorticoidinduced osteoporosis. In: Marcus R, Feldman D, Nelson DA, Rosen CJ (eds) Osteoporosis, 3rd edn. Elsevier, New York, pp 1135-1166
9. Khosla S, Amin S, Orwoll E (2008) Osteoporosis in men. Endocr Rev 29:441-464
10. Khosla S (2010) Update in male osteoporosis. J Clin Endocrinol Metab 95:3-10
11. Curtis JR, McClure LA, Delzell E et al (2009) Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med 24:956-962
12. Center JR, Bliuc D, Nguyen TV, Eisman JA (2007) Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 297:387-394
13. Miller PD, Silverman SL, Gold DTet al (2006) Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study. Osteoporos Int 17:85-90
14. Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17
15. Saag KG, Shane E, Boonen S, Marin F et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028-2039
16. Saag KG, Zanchetta JR, Devogelaer JP et al (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346-3355
17. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
18. Forteo Package Insert, Indianapolis, IN, USA: Eli Lilly and Company, 2010. http://pi.lilly.com/us/forteo-pi.pdf. Accessed 2 December 2010
19. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. 1994; Technical report series No. 84. http://whqlibdoc.who.int/trs/WHO-TRS-843.pdf. Accessed 2 December 2010
20. Feldstein AC, Nichols G, Orwoll E et al (2005) The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 16:953-962
21. Papaioannou A, Kennedy CC, Ioannidis G et al (2008) The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis study. Osteoporos Int 19:581-587
22. Cooper C, Campion G, Melton LJ III (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285-289
23. Adler RA (2006) The need for increasing awareness of osteoporosis in men. Clin Cornerstone 8(SUPPL. 3):S7-S13
24. Rao SS, Budhwar N, Ashfaque A (2010) Osteoporosis in men. Am Fam Physician 82:503-508
25. Qaseem A, Snow V, Shekelle P et al (2008) Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 148:680-684
26. Orwoll E, Blank JB, Barrett-Connor E et al (2005) Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study-a large observational study of the determinants of fracture in older men. Contemp Clin Trials 26:569-585
27. Lewis CE, Ewing SK, Taylor BC et al (2007) Predictors of nonspine fracture in elderly men: the MrOS study. J Bone Miner Res 22:211-219
28. Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 62:1515-1526
29. Van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993-1000